Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.62 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 10/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 10/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897724 | 0.92 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1MAPTKDM4EMEN1 | |
| SCHEMBL4498121 | 0.85 | MAPT (0.63) | GUCY1A1GUCY1B1MAPTKDM4EMEN1 | |
| SCHEMBL3896080 | 0.85 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1MAPTKDM4EMEN1 | |
| SCHEMBL3902014 | 0.81 | GUCY1A1 (0.69) | GUCY1A1GUCY1B1MAPTKDM4EMEN1 | |
| SCHEMBL3897756 | 0.80 | GUCY1A1 (0.94) | GUCY1A1GUCY1B1MAPTMEN1ALDH1A1 | |
| SCHEMBL4497227 | 0.79 | MEN1 (0.46) | GUCY1A1GUCY1B1MAPTKDM4EMEN1 | |
| SCHEMBL31282458 | 0.78 | ALDH1A1 (0.45) | GUCY1A1GUCY1B1MAPTKDM4EMEN1 | |
| SCHEMBL3909953 | 0.77 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1MAPTKDM4EMEN1 | |
| SCHEMBL3901927 | 0.76 | CNR2 (0.57) | GUCY1A1GUCY1B1CNR2CNR1 | |
| SCHEMBL14305552 | 0.75 | GUCY1A1 (0.48) | GUCY1A1GUCY1B1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | claimed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | disclosed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | disclosed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | disclosed |
| WO-2008005908-A2 | PYRIDOIMIDAZOLE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | CNR1, CNR2, OPRK1 | GUCY1A1 2264/4885GUCY1B1 2802/4885MAPT 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.